Encision Inc (ECIA) Fair Value & Analysis
Healthcare · US · Market cap $25.3K
Encision Inc
ECIA · US
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.4400 to $0.0015 (−99.7%) since Jun 24, 2026. Share price +650.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0002 – $0.4000 · fair‑value band $0.0015 – $0.0015 · the $0.0015 price screens above the $0.0015 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Encision Inc (ECIA) currently trades at $0.0015, while our model-based Fair Value estimate is $0.0015 — implying the stock looks roughly 0.2% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Encision Inc generated revenue of $6.3M at a net margin of -6.1%. Revenue declined 2.2% year over year. It earns a return on equity of -21.4%. Net debt stands at $1.1M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. It operates through two segments, Product and Service. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. The AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. It also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; AEM EndoShield 2 burn protection systems; AEM 2X enTouch scissors; and electrical engineering activities for external entities. In addition, the company markets AEM monitor product line that is used in conjunction with AEM instruments. It sells its products through a network of direct and …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Encision Inc reported revenue of $6.6M in FY2025 versus $7.5M in FY2021, a compound −3.4%/yr. Reported net income was −$220K in FY2025.
Is ECIA fairly valued? → Check now
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.95 | $182.39 | -55% |
| EssilorLuxottica Société anonyme ESLOF | $192.00 | $126.51 | -34% |
| HOYA Corporation HOCPY | $178.46 | $103.27 | -42% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| Becton, Dickinson and Company BDX | $147.79 | $124.26 | -16% |
| Alcon Inc ALC | $66.11 | $36.99 | -44% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Encision Inc (ECIA) undervalued?
What is the fair value of ECIA?
What is the quality score of ECIA?
What is the revenue of Encision Inc (ECIA)?
What is the net profit margin of ECIA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.